Genomic analysis identified strains of multidrug-resistant TB with additional resistance to the 6-month BPaL/M treatment regimen.
The guidelines recommend a 4-month drug regimen for adults and children with drug-susceptible TB, and a 6-month regimen for those with drug-resistant TB.
A meta-analysis of data from two trials found 6 months of levofloxacin in kids and adults exposed to MDR-TB was associated with a 60% relative reduction in TB incidence.
The Xpert MTB/RIF Ultra test is the first TB diagnosis test to meet the WHO's prequalification standards.
Researchers find that 10% of children living in an area of high TB transmission developed TB disease by the age of 10.
The report also spotlights the urgency of vaccines for pathogens such as group A Streptococcus and Klebsiella pneumoniae, which are increasingly resistant to antimicrobials.
WHO data show 8.2 million people were newly diagnosed with TB in 2023, up from 7.5 million in 2022 and the highest number recorded since 1995.
At 132 weeks from randomization, two bedaquiline-containing regimens maintained superiority compared with a 9-month injectable-based regimen.
Researchers found a 43% drop in DR-TB case notifications in a South African province after COVID-19 lockdowns were implemented.
The company has agreed to withdraw a secondary patent on the drug, which will allow generic suppliers to produce lower-cost versions.
